Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Piacenza – page 4

73 clinical trials in Piacenza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Piacenza at a glance
73
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

73 trials in Piacenza

Open in trial search

Ovarian cancer

Not recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Chronic myeloid leukaemia

Not recruiting

Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Oropharyngeal cancer+1

Not recruiting

Study on Electrochemotherapy with Bleomycin for Patients with Recurrent Oral and Oropharyngeal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Breast cancer

Not recruiting

Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:IRCCS Ospedale Policlinico San Martino

Ocular lymphoma

Not recruiting

Study on the Effectiveness of Doxycycline for Treating Newly Diagnosed Ocular Adnexal Marginal Zone Lymphoma Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Doxycycline
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Follicular lymphoma

Not recruiting

Study on Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma Not Eligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Fondazione Italiana Linfomi Ets

Chemotherapy cardiotoxicity attenuation

Not recruiting

Study on Dapagliflozin to Reduce Heart Damage from Chemotherapy in Breast Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione IRCCS Policlinico San Matteo

Pancreatic carcinoma

Not recruiting

Study on Quemliclustat and Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Arcus Biosciences Inc.

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Ibrutinib with Rituximab-CHOP for Untreated Patients with Diffuse Large B-cell Lymphoma at High Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Italiana Linfomi Ets

Follicular lymphoma

Not recruiting

Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Fondazione Italiana Linfomi Ets

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Piacenza

What the registry says about research in the country

01 Hematological Malignancies

Innovative clinical trials focusing on chronic myeloid leukemia, lymphomas, and various blood cancers, evaluating targeted therapies and combination treatments.

  • BCR-ABL1+ CML Treatment
  • Follicular Lymphoma Studies
  • Acute Myeloid Leukemia Research

Research emphasizes personalized treatment approaches and maintenance strategies for better patient outcomes.

02 Solid Tumors

Studies investigating advanced treatments for lung cancer, breast cancer, and pancreatic cancer, with focus on targeted and immunotherapy approaches.

  • NSCLC Treatment Sequences
  • Breast Cancer Hormone Therapy
  • Pancreatic Adenocarcinoma Studies

Trials explore novel drug combinations and treatment sequencing strategies.

03 Gynecologic Oncology

Clinical research examining treatments for ovarian cancer and related conditions, testing innovative therapeutic approaches and maintenance strategies.

  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer Studies

Focus on hormone receptor-positive cancers and targeted treatment combinations.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.